[See larger dataset of life science companies here.]
Biotech companies leverage biological systems to develop products and solutions.
Examples include Moderna, renowned for COVID-19 vaccines, Amgen, a leader in biologics and therapeutic innovations, and CRISPR Therapeutics, which is at the forefront of gene-editing technologies.
These companies often focus on advanced solutions, such as gene therapy (i.e., a medical treatment that uses genetic material to prevent or treat disease), monoclonal antibodies (i.e., lab-made proteins that bind to specific targets in the body to treat diseases), and cellular agriculture (i.e., lab grown foods).
The valuation of biotech companies has historically been driven by their pipeline potential, innovation, and ability to secure regulatory approvals.
During the pandemic, biotech valuations soared due to the demand for vaccines and treatments. By 2023, the sector recalibrated.
In 2024, biotech valuations remained volatile, heavily influenced by clinical trial outcomes and regulatory decisions.
Companies with late-stage pipelines or successful commercialization efforts maintained higher valuation while early-stage firms with unproven technologies faced downward pressure on valuation multiples.
Biotech Valuation Multiples
After removing the egregious outliers, the median revenue multiple for 279 biotech companies is 6.5x. The median EBITDA multiple for 45 biotech companies is 16.1x. The median PE ratio for 46 biotech companies is 17.0x.
Notice that the dataset for the revenue multiple calculation consists of 279 but EBITDA and PE multiples only have 45. Only 16% of public biotech companies in the dataset were profitable.
This is consistent with the fact that biotech companies are risky and spend years from inception developing products in the research and development phase. According to Forbes, 90% of biotech companies fail, and this includes all public and private companies.
When the company is profitable, the margins are not half bad.
The median gross margin of 148 biotech companies is 64%. The median EBITDA margin of 46 biotech companies is 20%. The median profit margin of 38 biotech companies is 13%.
Biotech Looking Ahead 2025
Looking ahead to 2025, several trends are likely to shape the valuation landscape for biotech companies.
First, the focus on precision medicine will continue to grow, as advancements in genomics and biomarkers enable more targeted and effective therapies.
Second, AI-driven drug discovery will gain momentum, with investors rewarding companies that demonstrate cost and time efficiencies in R&D pipelines through machine learning and data analytics.
Third, partnerships and licensing agreements with larger pharmaceutical companies will play a crucial role in enhancing valuation, particularly for smaller biotech firms looking to scale or navigate regulatory hurdles.
Download 2024 Data
To download the dataset consisting of ~270 companies in this analysis, enter your email address below to sign-up for the mailing list and the data set will be sent to your email directly. In some cases, it takes a few hours or a day to receive the email with the data set.